Trillium Therapeutics Inc.'s TTI-1612 Product Receives Orphan Drug Designation In Europe And The United States
TORONTO, Dec. 19 /CNW/ - Trillium Therapeutics Inc. (Trillium) today announced that its gastrointestinal product, TTI-1612, has been designated an Orphan Drug by the European Medicines Agency (EMEA), and the U.S. Food and
Drug Administration (FDA), for the prevention of necrotizing enterocolitis (NEC).